ASC Therapeutics

ASC Therapeutics is a gene therapy company headquartered in Silicon Valley, California, USA, developing gene therapies, in vivo gene editing, and allogeneic cell therapies for blood disorders and other rare diseases. ASC Therapeutics is led by a highly experienced management team with a global background and possesses unique technological platforms in gene and cell therapy. ASC Therapeutics is advancing multiple pioneering therapeutic programs based on three technology platforms: 1) In vivo gene therapy, focused on treating Hemophilia A, which received FDA IND clinical approval in July 2021; 2) In vivo gene editing, also targeting Hemophilia A; 3) Allogeneic cell therapy, with the first indication being the use of decidual stromal cells to treat steroid-refractory acute graft-versus-host disease.